Monte Rosa Therapeutics

Heart
#Cardiovascular disease #Molecular glue degrader #Monte Rosa Therapeutics #Phase I trial

Molecular glue degrader normalises key pathogenic drivers of ASCVD

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers.  Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More

#News

Lab professionals
#Acute inflammatory conditions #Cardiovascular disease #Molecular glue degrader #Monte Rosa Therapeutics #Phase I trial

Molecular glue degrader reduces systemic inflammation

Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.  “These remarkable interim data from our ongoing Phase I study of… Read More

#News

#Autoimmune disease #Monte Rosa Therapeutics #Preclinical development

Monte Rosa announces results for autoimmune disease treatment 

Biotechnology company Monte Rosa Therapeutics has released preclinical data on MRT-6160, a molecular glue degrader (MGD) to treat autoimmune and inflammatory diseases.  The findings reveal MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly in a spontaneous autoimmune… Read More

#News

Molecular glues
#Acute inflammatory conditions #Molecular glue degrader #Monte Rosa Therapeutics #Phase I trial

Molecular glue degrader progresses to Phase I trials

Monte Rosa Therapeutics has dosed the first subjects in a Phase I study evaluating MRT-8102, a NEK7-directed molecular glue degrader (MGD) being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.   Initial results from the Phase I study are expected in… Read More

#News

Medical professional examining mammogram
#Breast cancer #Molecular glue degrader #Monte Rosa Therapeutics #Oncology

Selective oral CDK2 degrader shows promise in breast cancer models

According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer.  Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More

#Cancer Research #News

#Collaboration #Immunology #License agreement #Monte Rosa Therapeutics #Novartis

Novartis and Monte Rosa partner on molecular glue degraders

Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture… Read More

#Business & Investment #News